Biogen Inc
NASDAQ:BIIB

Watchlist Manager
Biogen Inc Logo
Biogen Inc
NASDAQ:BIIB
Watchlist
Price: 146.47 USD -0.62% Market Closed
Market Cap: 21.3B USD
Have any thoughts about
Biogen Inc?
Write Note

P/S
Price to Sales

2.2
Current
3.4
Median
7.6
Industry
Lower than median
Lower than industry value

Price to Sales (P/S) ratio is a valuation multiple that compares a company’s market capitalization to its revenues. It is an indicator of the value that financial markets have placed on each dollar of a company’s sales.

P/S
2.2
=
Market Cap
21.2B USD
/
Revenue
9.6B USD
All Countries
Close
Revenue Growth P/S to Growth
US
Biogen Inc
NASDAQ:BIIB
Average P/S: 3 457 240.1
2.2
1%
2.2
FR
Pharnext SCA
OTC:PNEXF
38 027 714.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.6
20%
0.3
US
Amgen Inc
NASDAQ:AMGN
4.4
26%
0.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.1
10%
0.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.6
34%
0.3
US
E
Epizyme Inc
F:EPE
1 852.6
N/A N/A
AU
CSL Ltd
ASX:CSL
5.7
23%
0.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
23%
0.2
US
S
Seagen Inc
F:SGT
17.8
118%
0.2
NL
argenx SE
XBRU:ARGX
19.2
220%
0.1

P/S Forward Multiples

Forward P/S multiple is a version of the P/S ratio that uses forecasted revenue for the P/S calculation. 1-Year, 2-Years, and 3-Years forwards use revenue forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/S
2.2
2-Years Forward
P/S
2.2
3-Years Forward
P/S
2.1

See Also

Discover More